| Market Cap | 405.01K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -2.88M | Forward P/E | -0.10 | EPS next Y | - | 50D Avg Chg | -34.00% |
| Sales | 269.38k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -87.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -98.00% |
| Recommedations | - | Quick Ratio | 0.05 | Shares Outstanding | 79.41M | 52W Low Chg | 27.00% |
| Insider Own | 2.05% | ROA | -80.58% | Shares Float | 77.78M | Beta | 0.46 |
| Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.00510 |
| Gross Margin | -259.66% | Profit Margin | - | Avg. Volume | 88,324 | Target Price | - |
| Oper. Margin | -469.24% | Earnings Date | - | Volume | 9,885 | Change | 0.00% |
Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.
